What is the recommended diagnostic workup and treatment protocol for a pediatric patient with Wilms tumor?

Wilms Tumor: Diagnostic Workup and Treatment Protocol

For pediatric patients with suspected Wilms tumor, proceed directly to imaging with CT or MRI of the abdomen and chest (avoiding initial biopsy in most cases), followed by risk-stratified treatment based on tumor laterality, histology, and stage—with the primary approach being upfront nephrectomy for unilateral tumors or neoadjuvant chemotherapy for bilateral disease. 1

Diagnostic Workup

Initial Imaging Assessment

• Abdominal imaging: CT or MRI to evaluate the primary renal mass, assess resectability, and detect local extension
• Chest imaging: CT scan to identify pulmonary metastases (most common metastatic site)
• Do NOT perform initial biopsy for children with imaging findings consistent with bilateral renal tumors or unilateral tumor with known predisposing conditions 1

Critical Exception for Biopsy

Consider biopsy only when:

• Patient is >10 years of age with bilateral tumors or unilateral tumor with predisposing condition
• Concern exists for pathology other than Wilms tumor 1

Screening for High-Risk Patients

Children with predisposing genetic conditions (Denys-Drash, WAGR, Beckwith-Wiedemann, Frasier, Perlman syndromes) require surveillance with physical examination and abdominal ultrasound every 3 months until 7 years of age 1

Treatment Protocol: Algorithmic Approach

UNILATERAL WILMS TUMOR

Favorable Histology (Most Common)

The treatment pathway depends entirely on surgical timing and post-operative staging:

Primary Nephrectomy Approach (Standard in North America):

1. Radical nephrectomy with regional lymph node sampling as initial intervention
2. Post-operative chemotherapy assignment based on stage and histology:
   • Stage I without blastemal predominance: Regimen EE4A
   • Stage I with blastemal predominance OR Stage II-III without blastemal predominance: Regimen DD4A
   • Stage II-III with blastemal predominance: Augmented Regimen I (highest risk group)

Radiation Therapy Decisions:

• No RT: Stage I or Stage II disease, or complete response after neoadjuvant therapy
• Flank RT: Stage I-II requiring radiation
• Flank or whole abdominal irradiation (WAI): Local Stage III disease
• Timing: Start RT by day 10 post-surgery, no later than day 14 1

Anaplastic Histology (Unfavorable)

Focal Anaplasia:

• Stage I-III: Switch to Regimen DD4A with flank radiation (Stage I-II) or flank/WAI (Stage III)
  • Important caveat: Stage III focal anaplastic disease may warrant treatment intensification due to inferior outcomes in AREN0321 trial 1
• Stage IV: Switch to Revised Regimen UH-1 plus appropriate radiation fields

Diffuse Anaplasia (worse prognosis):

• Stage I: Regimen DD4A with flank radiation
• Stage II-IV: Revised Regimen UH-2 with stage-appropriate radiation
• Critical point: Higher radiation doses for Stage III diffuse anaplasia reduce local recurrence risk 1

Unresectable Diffuse Anaplasia:

• Neoadjuvant Revised Regimen UH-2
• Re-image at week 6; if progression occurs, perform nephrectomy OR rebiopsy
• If still unresectable, continue UH-2 and re-image at week 12 1

BILATERAL WILMS TUMOR

Initial Management (Neoadjuvant Approach Mandatory):

• Start with Regimen VAD (vincristine, dactinomycin, doxorubicin)
• Re-image at week 6 to assess response 1

Week 6 Decision Algorithm:

1. Complete response of renal tumors: Switch to Regimen DD4A, no flank radiation needed (but treat metastases if present)

2. Resectable by partial nephrectomy:

   • Perform nephron-sparing surgery (one or both sides) with regional lymph node sampling
   • Adjust chemotherapy based on histology:
     • FHWT without blastemal predominance → DD4A
     • FHWT with blastemal predominance → Regimen I
     • Anaplasia → Follow anaplastic protocols above

3. Partial response but not resectable: Continue VAD, re-image at week 12

4. Less than partial response or progression: Perform bilateral open biopsies if partial nephrectomy not feasible

   • Adjust chemotherapy based on biopsy results
   • Regimen I if blastemal predominance
   • Re-evaluate at week 12 1

Week 12 Management:

• If complete response: Switch to DD4A
• If less than complete response: Perform partial nephrectomy when feasible OR total nephrectomy with regional lymph node sampling
• Do not continue chemotherapy beyond 12 weeks without surgical intervention—further tumor shrinkage unlikely 1

Nephron-Sparing Surgery Priority: Preserve maximum kidney function through partial nephrectomy on one or both sides when feasible 1

METASTATIC DISEASE

For bilateral tumors with metastases, follow the bilateral tumor algorithm above with additional considerations:

• Whole lung irradiation for pulmonary metastases
• Radiation to other metastatic sites (e.g., lymph nodes, liver)
• Local staging determines flank/abdominal radiation independent of metastatic status 1

Critical Pitfalls to Avoid

1. Overlapping radiation fields: When treating both abdomen and lungs, plan both fields simultaneously during initial abdominal RT planning to minimize overlap, even if lung RT may not ultimately be needed 1

2. Biopsy-induced upstaging: Stage III designation from biopsy alone does NOT warrant radiation therapy 1

3. Anaplasia on biopsy: Any anaplasia detected on biopsy is considered diffuse, requiring more aggressive therapy 1

4. Delayed radiation: RT must begin within 10-14 days post-surgery; delays compromise local control 1

5. Inadequate lymph node sampling: Regional lymph node sampling is mandatory at nephrectomy for accurate staging 1

Surveillance After Treatment

• Imaging (CT, MRI, ultrasound, or chest x-ray) of chest and abdomen
• Every 3 months for 2 years, then every 6 months for additional 2 years
• High cure rates (>90% for favorable histology) shift focus to minimizing late effects and survivorship issues 1, 2

Nuances in Evidence

The NCCN 2025 guidelines 1 represent the most current and authoritative source, incorporating recent trial data including AREN0321 and AREN0534. The key philosophical difference between North American (COG/NWTSG) and European (SIOP) approaches—primary surgery versus neoadjuvant chemotherapy for unilateral tumors—persists, though both achieve excellent outcomes 3, 4. The NCCN guidelines favor upfront nephrectomy for unilateral disease but mandate neoadjuvant therapy for bilateral tumors to maximize nephron preservation.

All patients should be managed by a multidisciplinary team with pediatric oncology expertise 2, 5.